Sr. Director/Vice President Clinical Operations

Philadelphia, PA Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential […]

Cabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity against Anti-MuSK Expressing B Cells

Study to be presented by the laboratory of University of Pennsylvania professor Aimee Payne, M.D., Ph.D., Cabaletta co-founder and Scientific Advisory Board co-chair, as a highlighted abstract at the American Neurological Association (ANA) 2019 Annual Meeting in St. Louis PHILADELPHIA, Oct. 07, 2019 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc., a clinical stage biotechnology company focused […]

Cabaletta Bio Receives IND Clearance from FDA to Initiate First Clinical Trial of DSG3-CAART in Patients with Mucosal Pemphigus Vulgaris

First IND clearance of a product candidate derived from the CABA™ platform PHILADELPHIA, Oct. 01, 2019 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Company), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for the treatment of patients with B cell-mediated autoimmune diseases, today announced that it has received clearance […]

Cabaletta Bio Expands Management Team with Appointment of Brian Stalter as General Counsel

Mr. Stalter joins Cabaletta with more than 20 years of general corporate and deal-making experience in small biotech and large pharma organizations PHILADELPHIA, September 5, 2019 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases, today announced the appointment […]

Autoimmune Clinical Drug Development Expert, David J. Chang, M.D., M.P.H., Joins Cabaletta Bio as Chief Medical Officer

Extensive clinical development experience in autoimmune therapeutics complements existing Cabaletta core competencies in cell therapy translational research and manufacturing PHILADELPHIA, July 15, 2019 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, announced today the appointment of David J. Chang, M.D., […]

Vice President, Business Development

Philadelphia, PA Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential […]

Director/Senior Director of R&D Operations

Philadelphia, PA Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential […]

Cabaletta Bio Appoints Distinguished Immunotherapist and Cell Therapy Expert, Catherine Bollard, M.D., to its Board of Directors

RADNOR, Pa., April 02, 2019 (GLOBE NEWSWIRE)  – Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., Co-founder, Chief Executive Officer and Chairman, will present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11, […]

Cabaletta Bio to Present at the Cowen and Company 39th Annual Healthcare Conference

RADNOR, PA, March 6, 2019 – Cabaletta Bio, Inc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., Co-founder, Chief Executive Officer and Chairman, will present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11, 2019, at 10:00am […]

Director of GMP Quality

Philadelphia, PA Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential […]